US20110200694A1 - Promotors of Ceramide's Generation - Google Patents

Promotors of Ceramide's Generation Download PDF

Info

Publication number
US20110200694A1
US20110200694A1 US13/059,329 US200913059329A US2011200694A1 US 20110200694 A1 US20110200694 A1 US 20110200694A1 US 200913059329 A US200913059329 A US 200913059329A US 2011200694 A1 US2011200694 A1 US 2011200694A1
Authority
US
United States
Prior art keywords
radix
extract
rhizoma
petroleum ether
ceramide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/059,329
Inventor
Wan Zhang Qin
Chun Xin Yang
Fan Qi Kong
Hiroshi Nojiri
Shotaro Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongshan Hospital Fudan University
Kao Corp
Original Assignee
Zhongshan Hospital Fudan University
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN2009101187461A external-priority patent/CN101653561B/en
Priority claimed from CN 200910118747 external-priority patent/CN101653537B/en
Application filed by Zhongshan Hospital Fudan University, Kao Corp filed Critical Zhongshan Hospital Fudan University
Assigned to KAO CORPORATION, Zhongshan Hospital of Fudan University reassignment KAO CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KONG, FAN QI, QIN, WAN ZHANG, YANG, CHUN XIN, NOJIRI, HIROSHI, ITO, SHOTARO
Publication of US20110200694A1 publication Critical patent/US20110200694A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/898Orchidaceae (Orchid family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232Angelica
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284Atractylodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • A61K36/346Platycodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533Leonurus (motherwort)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/64Orobanchaceae (Broom-rape family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/70Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708Rheum (rhubarb)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/894Dioscoreaceae (Yam family)
    • A61K36/8945Dioscorea, e.g. yam, Chinese yam or water yam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a ceramide production-accelerating agent which can increase ceramide.
  • Ceramide which is a sphingolipid, is a lipid contained only in a small amount in whole living body. It has recently been reported that phenomena, such as proliferation, differentiation, and growth inhibition are induced by enhancing production of intracellular ceramide, and thus ceramide is an attractive intracellular signaling molecule capable of controlling proliferation, differentiation, apoptosis, and the like, of cells. Accordingly, it is thought that a ceramide production-accelerating substance is expected to have effects such as suppression of proliferation, induction of differentiation, and induction of apoptosis of animal cells, and consequently is expected to have therapeutic effects on diseases caused by abnormality of proliferation or differentiation of cells, such as inflammatory diseases and malignant tumors (Non-Patent Document 1).
  • ceramide which is a sphingolipid, makes up at least half of lipids contained in horny layer, which is outermost layer of skin, and plays an important role in moisturizing function and barrier function of skin. Ceramide is produced in and secreted from keratinocytes and then functions as forming a lamella structure in intracellular space of the horny layer.
  • ceramide shows bone resorption inhibitory action, bone reinforcing action, and alveolar bone loss inhibitory action, is useful for prevention and amelioration of bone and joint diseases, such as osteoporosis, bone fracture, lumbago, and rheumatism (Patent Document 1), and further that it is effective for prevention of periodontal disease (Patent Document 2). Accordingly, a ceramide production-accelerating substance is also expected to show therapeutic effect on such diseases.
  • ceramide is reported to show action of giving body and elasticity to hair and improving feeling thereof (Patent Document 3), and thus a ceramide production-accelerating substance is also expected to show such effects.
  • Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma are all medicinal plants which have been used since a long time ago as a folk medicine or herbal medicine.
  • Angelicae Dahuricae Radix is used for the purpose of alleviation of fever, pain relief, detoxication, pus discharge, and the like as a harval medicine, and its ether extract is reported to show blood pressure elevation action and respiratory movement excitation action (Non-Patent Document 2).
  • Rehmanniae Radix is applied, as a tonic medicine or antipyretic drug, to diabetes, prostatomegaly, senile lumbago, cataract, and the like, and is used as a Chinese medicine for the purpose of blood replenishment, tonic, alleviation of fever, antidiarrheal, laxativeness, and the like. Also, a water extract or ethanol extract of Rehmanniae Radix is reported to show hypoglycemic or hyperglycemic inhibitory action, laxativeness, and diuretic action (Non-Patent Document 3).
  • Atractylodis Rhizoma is used for the purpose of stomach strengthening, intestinal function regulation, diuresis, suppression of sweating, and the like, and is reported to show urinary volume increasing action and hyperglycemic action.
  • Glycyrrhizae Radix is known as a source for glycyrrhizinic acid and it is widely used as an antitussive or expectorant drug, or a remedy for gastrointestinal ulcer, and is used as a Chinese medicine for the purpose of pain relief, detoxication, and the like.
  • Non-Patent Document 4 An extract of Glycyrrhizae Radix is reported to show remarkable gastric inhibitory action, gastrointestinal ulcer recovery accelerating action, antispasmodic action, antitussive action, and the like.
  • Rhei Rhizoma is used as a purgative and a stomachic, and is used as a Chinese medicine for the purpose of anti-inflammation, purgation, and detoxication.
  • Bletilla Tuber is used as a Chinese medicine for the purpose of hemostasis, pain relief, and chronic gastritis (Non-Patent Document 5).
  • Polygoni Multiflori Radix is used as a Chinese medicine for dizziness or headache due to anemia, and insomnia.
  • Platycodi Radix is used as an antitussive and expectorant drug, and is known to have saliva secretion and respiratory secretion accelerating action.
  • Leonuri Herba is used against various symptoms of women before and after childbirth as a medicine for blood activation, increased metabolism, and energy supplement, and is reported to be effective against edema due to nephritis (Non-Patent Document 6).
  • Dioscoreae Rhizoma is used for the purpose of nutritional fortification, antitussive, antidiarrheal, and dryness relief, and is reported to show antihypertensive action and androgenic hormone enhancing action (Non-Patent Document 7).
  • Non-Patent Document 1 Sphingolipid targets in cancer therapy, David E. Modrak et al., Molecular Cancer Therapeutics, 2006, 5(2): 200-8
  • Non-Patent Document 2 Tennen iyaku shigengaku (Natural Medicinal Resources) (2nd Edition, edited by Tadahiro TAKEDA et al., and published by Hirokawa-shoten), pp. 215-216
  • Non-Patent Document 3 Tennen iyaku shigengaku (Natural Medicinal Resources) (2nd Edition, edited by Tadahiro TAKEDA et al., and published by Hirokawa-shoten), pp.
  • Non-Patent Document 4 Wakan yakubutsugaku (Japanese, Chinese Medicines) (1st Edition, edited by Keijiro TAKAGI et al., and published by Nanzando), pp. 72-73.
  • Non-Patent Document 5 Tennen iyaku shigengaku (Natural Medicinal Resources) (2nd Edition, edited by Tadahiro TAKEDA et al., and published by Hirokawa-shoten), pp.
  • Non-Patent Document 6 Wakan Yakuyo shokubutsu (Japanese and Chinese Medicinal Plants) (20th Edition, edited by Tatsuo KARIBE, and published by Hirokawa-shoten), p. 72
  • Non-Patent Document 7 Tennen iyaku shigengaku (Natural Medicinal Resources) (2nd Edition, edited by Tadahiro TAKEDA et al., and published by Hirokawa-shoten), pp. 263-264
  • the present invention provides pharmaceuticals, cosmetics, and the like for accelerating intracellular ceramide production.
  • the present invention provides cosmetics or pharmaceuticals capable of restoring or maintaining barrier function and moisturizing function of skin.
  • the present inventors have searched for highly safe natural materials, and have found that an extract of each of Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma shows ceramide production-accelerating action and can be used as a ceramide production accelerating-agent.
  • the present invention relates to a ceramide production-accelerating agent containing a plant selected from Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma, or an extract thereof as an active ingredient.
  • a plant selected from Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma, or an extract thereof as an active ingredient.
  • the extract of Angelicae Dahuricae Radix, Atractylodis Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, or Dioscoreae Rhizoma may be a petroleum ether extract prepared by using a petroleum ether as an extraction solvent.
  • the extract of Rehmanniae Radix or Glycyrrhizae Radix may be an ethanol extract prepared by successively using a petroleum ether and ethanol as extraction solvents.
  • the extract of Rhei Rhizoma may be a water extract prepared by successively using a petroleum ether, ethanol, and water as extraction solvents.
  • the present invention relates to use of a plant selected from Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma or an extract thereof for the manufacture of a ceramide production-accelerating agent.
  • a plant selected from Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma or an extract thereof for the manufacture of a ceramide production-accelerating agent.
  • the present invention relates to a moisturizing agent containing a plant selected from Leonuri Herba and Dioscoreae Rhizoma or an extract thereof as an active ingredient.
  • the extract of the Leonuri Herba or Dioscoreae Rhizoma in the moisturizing agent may be a petroleum ether extract prepared by using a petroleum ether as an extraction solvent.
  • the present invention relates to use of a plant selected from Leonuri Herba and Dioscoreae Rhizoma or an extract thereof for the manufacture of a moisturizing agent.
  • the ceramide production-accelerating agent of the present invention increases intracellular ceramide and is useful as pharmaceuticals, and the like, for preventing or ameliorating inflammatory disease, bone and joint disease, periodontal disease, and the like, or as cosmetics, and the like, for giving body and strength to hair and improving the feeling thereof.
  • the present inventors have searched for highly safe natural materials, and found that certain plants or extract thereof has ceramide production-accelerating action and they are useful as pharmaceuticals or cosmetics which can restore or maintain barrier function and moisturizing function of horny layer.
  • the ceramide production-accelerating agent of the present invention is useful as cosmetics, pharmaceuticals, and the like, for restoring or maintaining barrier function and moisturizing function of skin by increasing ceramide in horny layer.
  • Angelicae Dahuricae Radix is originated from Angelica dahurica Bentham et Hooker belonging to Umbelliferae;
  • Rehmanniae Radix is originated from Rehmannia glutinosa Liboschitz var. purpurea Makino or Rehmannia glutinosa Liboschitz belonging to Scrophulariaceae;
  • Atractylodis Rhizoma is originated from Atractylodes ovata De Candolle belonging to Compositae;
  • Glycyrrhizae Radix is originated from Glycyrrhiza uralensis Fisher or G.
  • Rhei Rhizoma is originated from Rheum palmatum L. belonging to Polygonaceae
  • Bletilla Tuber is originated from Bletilla striata Reichb. fil. belonging to Orchidaceae
  • Polygoni Multiflori Radix is originated from Polygonum multiflorum Thunb. belonging to Polygonaceae
  • Whole plant body, leaves, barks, branches, fruits, or roots of the above plants may be used directly or after pulverization, preferably roots of Angelicae Dahuricae Radix and Rehmanniae Radix; roots, and stems of Atractylodis Rhizoma; roots and rhizomes of Glycyrrhizae Radix and Rhei Rhizoma; tubers of Bletilla Tuber; roots of Polygoni Multiflori Radix; roots of Platycodi Radix; aboveground parts of Leonuri Herba; and roots and stems of Dioscoreae Rhizoma are used.
  • the plant extracts of the present invention include extracts prepared by providing the parts to be used of the above-mentioned plants directly or after drying and cutting into a suitable size or pulverization before extraction therefrom, and also include fractions (ingredients) showing higher activity prepared by further isolation and purification thereof.
  • the extraction may be performed by immersion into a solvent at room temperature or under heating or by solvent extraction conducted by using an extraction equipment such as Soxhlet extractor, and further by extraction through distillation such as steam distillation, supercritical fluid extraction using supercritical carbon dioxide, or compression method to obtain extract by compression.
  • an extraction equipment such as Soxhlet extractor
  • distillation such as steam distillation, supercritical fluid extraction using supercritical carbon dioxide, or compression method to obtain extract by compression.
  • Either polar solvent or non-polar solvent, or a mixture thereof, may be used as solvent for extraction used in the solvent extraction.
  • solvent for extraction examples thereof include water; alcohols such as methanol, ethanol, propanol, and butanol; polyols such as ethylene glycol, propylene glycol, and butylene glycol; ketones such as acetone and methylethylketone; esters such as methyl acetate and ethyl acetate; linear or cyclic ethers such as tetrahydrofuran and diethylether; polyethers such as polyethylene glycol; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; hydrocarbons such as hexane, cyclohexane and petroleum ether; aromatic hydrocarbons such as benzene and toluene; pyridines; supercritical carbon dioxide; fats and oils, waxes, and other oils, which may be used alone or
  • the extraction is preferably performed by extraction using 1 to 50 parts by mass of the solvent relative to 1 part by mass of the plant at a temperature of 4 to 100° C., more preferably 20 to 80° C., for 1 hour to 30 days, more preferably 1 hour to 10 days.
  • Examples of the methods of isolating and purifying the extract include an activated charcoal treatment, liquid-liquid distribution, column chromatography, liquid chromatography, gel filtration, and precision distillation. If needed, an additional treatment, such as deodorization and decolorization, may be performed following a known method.
  • prepared plant extract of the present invention may be used as a liquid extraction or a fraction directly, or may be used as a diluted liquid prepared by dilution thereof with an appropriate solvent, an extract, a dried powder, or a paste prepared through concentration under heat or under reduce pressure may be used.
  • the plant extract may be freeze-dried, and upon using may be diluted with a solvent which is commonly used for extraction, such as water, ethanol, propylene glycol, butylene glycol, a water-ethanol mixture, a water-propylene glycol mixture, and a water-butylene glycol mixture. It may also be used in the form of being contained in a vesicle, such as liposome, or a microcapsule, and the like.
  • the plants or the extracts thereof of the present invention show the action of increasing an amount of ceramide in a normal human keratinocyte, as shown in below Examples.
  • the moisturizing function herein means a function which gives the skin appropriate moisture to make the skin soft and make the skin smooth and beautiful.
  • the barrier function herein means a function which prevents evaporation of the moisture in the body to prevent the body from drying out and prevent invasion of foreign substance from outside into the body.
  • the plants or the extracts thereof of the present invention can be used as a ceramide production-accelerating agent, a moisturizing agent, or a barrier reinforcing agent, and can be used for manufacturing the ceramide production-accelerating agent, moisturizing agent, or barrier reinforcing agent.
  • the ceramide production-accelerating agent or moisturizing agent can be used as pharmaceuticals, quasi drugs, and cosmetics for increasing ceramide in horny layer and restoring or maintaining barrier function and moisturizing function of the skin.
  • the ceramide production-accelerating agent is expected to exhibit effects such as suppression of proliferation of animal cells, induction of differentiation, and induction of apoptosis, therefore, it can be used as pharmaceuticals or quasi drugs for preventing or treating diseases caused by abnormal proliferation or differentiation of cells, such as inflammatory diseases and malignant tumors (the above-described Non-Patent Document 1), and also can be used as pharmaceuticals or quasi drugs for prevention and amelioration of bone and joint diseases, such as osteoporosis, fracture of bone, lumbago, and rheumatism, and as pharmaceuticals or quasi drugs for prevention and amelioration of periodontal disease (the above-described Patent Documents 1 and 2).
  • the ceramide production-accelerating agent can be used as quasi drugs or cosmetics which are based on the concept of ceramide production-acceleration and moisturizing, and if needed, on which such a concept is indicated.
  • the dosage form in the case where the ceramide production-accelerating agent or moisturizing agent of the present invention is used as pharmaceuticals may be either oral administration with tablets, capsules, granules, powders, syrups, and the like, or parenteral administration with injections, external preparations, suppositories, transdermal drugs, and the like.
  • the plants or the extracts thereof of the present invention may be used alone, or in appropriate combination with a pharmacologically acceptable excipient, binder, extender, disintegrant, surfactant, lubricant, dispersing agent, buffering agent, preservative, corrigent, fragrance, film forming agent, carrier, diluent, and the like.
  • the content of the plants of the present invention in the preparation is preferably 0.01 to 20% by mass, more preferably, 0.05 to 10% by mass in terms of dry solid content, and the content of the plant extract is preferably 0.0001 to 10% by mass, more preferably, 0.001 to 5% by mass in terms of solid content.
  • a daily dose per one adult, as the plants or the extracts thereof, (in terms of dry solid content) is preferably 0.001 to 1000 mg, more preferably, 0.01 to 100 mg.
  • the ceramide production-accelerating agent and moisturizing agent of the present invention when used as quasi drugs or cosmetics, they may be formed as an external preparation for the skin, a detergent, or make-up cosmetics, and may be provided as various dosage forms, including lotions, milky lotions (emulsions), gels, creams, ointments, powders, and granules, in accordance with intended use.
  • These quasi drugs and cosmetics with various dosage forms may be prepared by using the plants or the extracts of the present invention alone, or in appropriate combination with an oily ingredient, a moisturizing agent, a powder, a pigment, an emulsifying agent, a solubilizing agent, a detergent, an ultraviolet absorber, a thickening agent, a medicinal ingredient, a fragrance, a resin, an antimicrobial-antifungal agent, a plant extract, an alcohol, and the like.
  • the medicinal ingredient include other moisturizing ingredients such as sodium hyaluronate.
  • the content of the plant of the present invention in the quasi drug or cosmetics is preferably 0.01 to 100% by mass, more preferably, 0.05 to 70% by mass, as a dry solid ingredient. Meanwhile, the content of the extract thereof is generally preferably 0.00001 to 100% by mass, more preferably, 0.0001 to 70% by mass, in terms of solid content.
  • NHEK (F) Normal human epidermal keratinocyte
  • EpiLife-KG2 product of KURABO Industries Ltd.
  • the culture medium were changed to EpiLife-KG2 (without additive growth factor), and each of the above test solutions and each control solution were added thereto. After culturing for 3 days, cells were collected from the wells one by one.
  • Lipid was extracted from the collected cells following Bligh and Dyer method. After the extraction, lipid extract was dried to solid with nitrogen, the solid was dissolved again in a mixed liquid of chloroform and methanol, to prepare a lipid sample. The amount of protein was quantified by BCA method.
  • the extracted lipid was analyzed with a thin-layer chromatography (TLC).
  • TLC thin-layer chromatography
  • the values in the Table are relative values to the ceramide amount of control (a sample added the above-mentioned control solution) set as 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention provides a pharmaceutical composition or a cosmetic product which can accelerate production of ceramide in cells. The ceramide production-accelerating agent contains a plant selected from the group consisting of Radix Heraclei Scabridi, Rhizoma Dioscoreae, Radix Rehmanniae, Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Radix Et Rhizoma Rhei, Pseudobulbus Bletillae, Radix Polygoni Multiflori, Radix Platycodi, and Herba Leonuli, or an extract thereof as an active ingredient. Further, the present invention provides a moisturizing agent containing a plant selected from the group consisting of Herba Leonuri and Rhizoma Dioscoreae, or an extract thereof as an active ingredient.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a ceramide production-accelerating agent which can increase ceramide.
  • BACKGROUND OF THE INVENTION
  • Ceramide, which is a sphingolipid, is a lipid contained only in a small amount in whole living body. It has recently been reported that phenomena, such as proliferation, differentiation, and growth inhibition are induced by enhancing production of intracellular ceramide, and thus ceramide is an attractive intracellular signaling molecule capable of controlling proliferation, differentiation, apoptosis, and the like, of cells. Accordingly, it is thought that a ceramide production-accelerating substance is expected to have effects such as suppression of proliferation, induction of differentiation, and induction of apoptosis of animal cells, and consequently is expected to have therapeutic effects on diseases caused by abnormality of proliferation or differentiation of cells, such as inflammatory diseases and malignant tumors (Non-Patent Document 1).
  • In addition, ceramide, which is a sphingolipid, makes up at least half of lipids contained in horny layer, which is outermost layer of skin, and plays an important role in moisturizing function and barrier function of skin. Ceramide is produced in and secreted from keratinocytes and then functions as forming a lamella structure in intracellular space of the horny layer.
  • However, there are many reports showing that normal metabolism of ceramide is prevented and thus the amount of ceramide in horny layer is decreased to cause impairment of moisturizing function, barrier function, and the like, of the skin in dermal diseases such as dry skin, xerosis, atopic dermatitis, senile xerosis and psoriasis.
  • Therefore, a method of supplying the decreased ceramides topically to treat such diseases has been attempted. However, problems included in this method are, for example, difficulty of long-term effect and low stability, and the like.
  • Meanwhile, it is reported that ceramide shows bone resorption inhibitory action, bone reinforcing action, and alveolar bone loss inhibitory action, is useful for prevention and amelioration of bone and joint diseases, such as osteoporosis, bone fracture, lumbago, and rheumatism (Patent Document 1), and further that it is effective for prevention of periodontal disease (Patent Document 2). Accordingly, a ceramide production-accelerating substance is also expected to show therapeutic effect on such diseases.
  • Moreover, ceramide is reported to show action of giving body and elasticity to hair and improving feeling thereof (Patent Document 3), and thus a ceramide production-accelerating substance is also expected to show such effects.
  • Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma are all medicinal plants which have been used since a long time ago as a folk medicine or herbal medicine. Specifically, Angelicae Dahuricae Radix is used for the purpose of alleviation of fever, pain relief, detoxication, pus discharge, and the like as a harval medicine, and its ether extract is reported to show blood pressure elevation action and respiratory movement excitation action (Non-Patent Document 2). Rehmanniae Radix is applied, as a tonic medicine or antipyretic drug, to diabetes, prostatomegaly, senile lumbago, cataract, and the like, and is used as a Chinese medicine for the purpose of blood replenishment, tonic, alleviation of fever, antidiarrheal, laxativeness, and the like. Also, a water extract or ethanol extract of Rehmanniae Radix is reported to show hypoglycemic or hyperglycemic inhibitory action, laxativeness, and diuretic action (Non-Patent Document 3). Atractylodis Rhizoma is used for the purpose of stomach strengthening, intestinal function regulation, diuresis, suppression of sweating, and the like, and is reported to show urinary volume increasing action and hyperglycemic action. Glycyrrhizae Radix is known as a source for glycyrrhizinic acid and it is widely used as an antitussive or expectorant drug, or a remedy for gastrointestinal ulcer, and is used as a Chinese medicine for the purpose of pain relief, detoxication, and the like. An extract of Glycyrrhizae Radix is reported to show remarkable gastric inhibitory action, gastrointestinal ulcer recovery accelerating action, antispasmodic action, antitussive action, and the like (Non-Patent Document 4). Rhei Rhizoma is used as a purgative and a stomachic, and is used as a Chinese medicine for the purpose of anti-inflammation, purgation, and detoxication. Bletilla Tuber is used as a Chinese medicine for the purpose of hemostasis, pain relief, and chronic gastritis (Non-Patent Document 5). Polygoni Multiflori Radix is used as a Chinese medicine for dizziness or headache due to anemia, and insomnia. Platycodi Radix is used as an antitussive and expectorant drug, and is known to have saliva secretion and respiratory secretion accelerating action. Leonuri Herba is used against various symptoms of women before and after childbirth as a medicine for blood activation, increased metabolism, and energy supplement, and is reported to be effective against edema due to nephritis (Non-Patent Document 6). Dioscoreae Rhizoma is used for the purpose of nutritional fortification, antitussive, antidiarrheal, and dryness relief, and is reported to show antihypertensive action and androgenic hormone enhancing action (Non-Patent Document 7).
  • However, it has not so far been known that these plants show a ceramide production-accelerating effect and a moisturizing effect.
  • [Patent Document 1] JP-A-2001-158736 [Patent Document 2] JP-A-2001-158735 [Patent Document 3] JP-A-H10-152421
  • [Non-Patent Document 1] Sphingolipid targets in cancer therapy, David E. Modrak et al., Molecular Cancer Therapeutics, 2006, 5(2): 200-8
    [Non-Patent Document 2] Tennen iyaku shigengaku (Natural Medicinal Resources) (2nd Edition, edited by Tadahiro TAKEDA et al., and published by Hirokawa-shoten), pp. 215-216
    [Non-Patent Document 3] Tennen iyaku shigengaku (Natural Medicinal Resources) (2nd Edition, edited by Tadahiro TAKEDA et al., and published by Hirokawa-shoten), pp. 132-133
    [Non-Patent Document 4] Wakan yakubutsugaku (Japanese, Chinese Medicines) (1st Edition, edited by Keijiro TAKAGI et al., and published by Nanzando), pp. 72-73.
    [Non-Patent Document 5] Tennen iyaku shigengaku (Natural Medicinal Resources) (2nd Edition, edited by Tadahiro TAKEDA et al., and published by Hirokawa-shoten), pp. 263-264
    [Non-Patent Document 6] Wakan Yakuyo shokubutsu (Japanese and Chinese Medicinal Plants) (20th Edition, edited by Tatsuo KARIBE, and published by Hirokawa-shoten), p. 72
    [Non-Patent Document 7] Tennen iyaku shigengaku (Natural Medicinal Resources) (2nd Edition, edited by Tadahiro TAKEDA et al., and published by Hirokawa-shoten), pp. 263-264
  • SUMMARY OF THE INVENTION
  • The present invention provides pharmaceuticals, cosmetics, and the like for accelerating intracellular ceramide production. In addition, the present invention provides cosmetics or pharmaceuticals capable of restoring or maintaining barrier function and moisturizing function of skin.
  • The present inventors have searched for highly safe natural materials, and have found that an extract of each of Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma shows ceramide production-accelerating action and can be used as a ceramide production accelerating-agent.
  • The present invention relates to a ceramide production-accelerating agent containing a plant selected from Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma, or an extract thereof as an active ingredient.
  • The extract of Angelicae Dahuricae Radix, Atractylodis Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, or Dioscoreae Rhizoma may be a petroleum ether extract prepared by using a petroleum ether as an extraction solvent. The extract of Rehmanniae Radix or Glycyrrhizae Radix may be an ethanol extract prepared by successively using a petroleum ether and ethanol as extraction solvents. The extract of Rhei Rhizoma may be a water extract prepared by successively using a petroleum ether, ethanol, and water as extraction solvents.
  • Also, the present invention relates to use of a plant selected from Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma or an extract thereof for the manufacture of a ceramide production-accelerating agent.
  • Moreover, the present invention relates to a moisturizing agent containing a plant selected from Leonuri Herba and Dioscoreae Rhizoma or an extract thereof as an active ingredient.
  • The extract of the Leonuri Herba or Dioscoreae Rhizoma in the moisturizing agent may be a petroleum ether extract prepared by using a petroleum ether as an extraction solvent.
  • Also, the present invention relates to use of a plant selected from Leonuri Herba and Dioscoreae Rhizoma or an extract thereof for the manufacture of a moisturizing agent.
  • The ceramide production-accelerating agent of the present invention increases intracellular ceramide and is useful as pharmaceuticals, and the like, for preventing or ameliorating inflammatory disease, bone and joint disease, periodontal disease, and the like, or as cosmetics, and the like, for giving body and strength to hair and improving the feeling thereof.
  • The present inventors have searched for highly safe natural materials, and found that certain plants or extract thereof has ceramide production-accelerating action and they are useful as pharmaceuticals or cosmetics which can restore or maintain barrier function and moisturizing function of horny layer.
  • The ceramide production-accelerating agent of the present invention is useful as cosmetics, pharmaceuticals, and the like, for restoring or maintaining barrier function and moisturizing function of skin by increasing ceramide in horny layer.
  • DETAILED DESCRIPTION OF THE INVENTION
  • In the present invention, Angelicae Dahuricae Radix is originated from Angelica dahurica Bentham et Hooker belonging to Umbelliferae; Rehmanniae Radix is originated from Rehmannia glutinosa Liboschitz var. purpurea Makino or Rehmannia glutinosa Liboschitz belonging to Scrophulariaceae; Atractylodis Rhizoma is originated from Atractylodes ovata De Candolle belonging to Compositae; Glycyrrhizae Radix is originated from Glycyrrhiza uralensis Fisher or G. glabra Linne belonging to Leguminosae; Rhei Rhizoma is originated from Rheum palmatum L. belonging to Polygonaceae; Bletilla Tuber is originated from Bletilla striata Reichb. fil. belonging to Orchidaceae; Polygoni Multiflori Radix is originated from Polygonum multiflorum Thunb. belonging to Polygonaceae; Platycodi Radix is originated from Platycodon grandiflorum A. De Candolle belonging to Campanulaceae; Leonuri Herba is originated from Leonurus sibiricus L. belonging to Laminaceae; and Dioscoreae Rhizoma is originated from Dioscorea japonica Thunberg belonging to Dioscoreaceae.
  • Whole plant body, leaves, barks, branches, fruits, or roots of the above plants may be used directly or after pulverization, preferably roots of Angelicae Dahuricae Radix and Rehmanniae Radix; roots, and stems of Atractylodis Rhizoma; roots and rhizomes of Glycyrrhizae Radix and Rhei Rhizoma; tubers of Bletilla Tuber; roots of Polygoni Multiflori Radix; roots of Platycodi Radix; aboveground parts of Leonuri Herba; and roots and stems of Dioscoreae Rhizoma are used.
  • The plant extracts of the present invention include extracts prepared by providing the parts to be used of the above-mentioned plants directly or after drying and cutting into a suitable size or pulverization before extraction therefrom, and also include fractions (ingredients) showing higher activity prepared by further isolation and purification thereof.
  • The extraction may be performed by immersion into a solvent at room temperature or under heating or by solvent extraction conducted by using an extraction equipment such as Soxhlet extractor, and further by extraction through distillation such as steam distillation, supercritical fluid extraction using supercritical carbon dioxide, or compression method to obtain extract by compression.
  • Either polar solvent or non-polar solvent, or a mixture thereof, may be used as solvent for extraction used in the solvent extraction. Examples thereof include water; alcohols such as methanol, ethanol, propanol, and butanol; polyols such as ethylene glycol, propylene glycol, and butylene glycol; ketones such as acetone and methylethylketone; esters such as methyl acetate and ethyl acetate; linear or cyclic ethers such as tetrahydrofuran and diethylether; polyethers such as polyethylene glycol; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; hydrocarbons such as hexane, cyclohexane and petroleum ether; aromatic hydrocarbons such as benzene and toluene; pyridines; supercritical carbon dioxide; fats and oils, waxes, and other oils, which may be used alone or in combinations of two or more, and the extraction may be performed repeatedly with changing of solvents. Among these solvents, it is preferable to use water, ethanol, propylene glycol, butylene glycol, petroleum ether, and the like; more preferably, a mixture of water and ethanol, or petroleum ether.
  • In the case where, for example, water, alcohol, hydrocarbon or a mixture of water and an alcohol is used for extraction, the extraction is preferably performed by extraction using 1 to 50 parts by mass of the solvent relative to 1 part by mass of the plant at a temperature of 4 to 100° C., more preferably 20 to 80° C., for 1 hour to 30 days, more preferably 1 hour to 10 days.
  • Examples of the methods of isolating and purifying the extract include an activated charcoal treatment, liquid-liquid distribution, column chromatography, liquid chromatography, gel filtration, and precision distillation. If needed, an additional treatment, such as deodorization and decolorization, may be performed following a known method.
  • Thus prepared plant extract of the present invention may be used as a liquid extraction or a fraction directly, or may be used as a diluted liquid prepared by dilution thereof with an appropriate solvent, an extract, a dried powder, or a paste prepared through concentration under heat or under reduce pressure may be used. The plant extract may be freeze-dried, and upon using may be diluted with a solvent which is commonly used for extraction, such as water, ethanol, propylene glycol, butylene glycol, a water-ethanol mixture, a water-propylene glycol mixture, and a water-butylene glycol mixture. It may also be used in the form of being contained in a vesicle, such as liposome, or a microcapsule, and the like.
  • The plants or the extracts thereof of the present invention show the action of increasing an amount of ceramide in a normal human keratinocyte, as shown in below Examples.
  • Ceramide plays an important role in moisturizing function and barrier function of the skin (Genji IMOKAWA, Koshokaishi 1(4), 250-253, 1991). The moisturizing function herein means a function which gives the skin appropriate moisture to make the skin soft and make the skin smooth and beautiful. The barrier function herein means a function which prevents evaporation of the moisture in the body to prevent the body from drying out and prevent invasion of foreign substance from outside into the body.
  • Accordingly, the plants or the extracts thereof of the present invention can be used as a ceramide production-accelerating agent, a moisturizing agent, or a barrier reinforcing agent, and can be used for manufacturing the ceramide production-accelerating agent, moisturizing agent, or barrier reinforcing agent. The ceramide production-accelerating agent or moisturizing agent can be used as pharmaceuticals, quasi drugs, and cosmetics for increasing ceramide in horny layer and restoring or maintaining barrier function and moisturizing function of the skin. The ceramide production-accelerating agent is expected to exhibit effects such as suppression of proliferation of animal cells, induction of differentiation, and induction of apoptosis, therefore, it can be used as pharmaceuticals or quasi drugs for preventing or treating diseases caused by abnormal proliferation or differentiation of cells, such as inflammatory diseases and malignant tumors (the above-described Non-Patent Document 1), and also can be used as pharmaceuticals or quasi drugs for prevention and amelioration of bone and joint diseases, such as osteoporosis, fracture of bone, lumbago, and rheumatism, and as pharmaceuticals or quasi drugs for prevention and amelioration of periodontal disease (the above-described Patent Documents 1 and 2). Moreover, it can be used as quasi drugs or cosmetics for giving body and elasticity to the hair, and improving the feeling thereof (the above-described Patent Document 3). The ceramide production-accelerating agent can be used as quasi drugs or cosmetics which are based on the concept of ceramide production-acceleration and moisturizing, and if needed, on which such a concept is indicated.
  • The dosage form in the case where the ceramide production-accelerating agent or moisturizing agent of the present invention is used as pharmaceuticals may be either oral administration with tablets, capsules, granules, powders, syrups, and the like, or parenteral administration with injections, external preparations, suppositories, transdermal drugs, and the like. When preparing the pharmaceutical preparation, the plants or the extracts thereof of the present invention may be used alone, or in appropriate combination with a pharmacologically acceptable excipient, binder, extender, disintegrant, surfactant, lubricant, dispersing agent, buffering agent, preservative, corrigent, fragrance, film forming agent, carrier, diluent, and the like. The content of the plants of the present invention in the preparation is preferably 0.01 to 20% by mass, more preferably, 0.05 to 10% by mass in terms of dry solid content, and the content of the plant extract is preferably 0.0001 to 10% by mass, more preferably, 0.001 to 5% by mass in terms of solid content. When the ceramide production-accelerating agent of the present invention is used as pharmaceuticals, a daily dose per one adult, as the plants or the extracts thereof, (in terms of dry solid content) is preferably 0.001 to 1000 mg, more preferably, 0.01 to 100 mg.
  • Moreover, when the ceramide production-accelerating agent and moisturizing agent of the present invention are used as quasi drugs or cosmetics, they may be formed as an external preparation for the skin, a detergent, or make-up cosmetics, and may be provided as various dosage forms, including lotions, milky lotions (emulsions), gels, creams, ointments, powders, and granules, in accordance with intended use. These quasi drugs and cosmetics with various dosage forms may be prepared by using the plants or the extracts of the present invention alone, or in appropriate combination with an oily ingredient, a moisturizing agent, a powder, a pigment, an emulsifying agent, a solubilizing agent, a detergent, an ultraviolet absorber, a thickening agent, a medicinal ingredient, a fragrance, a resin, an antimicrobial-antifungal agent, a plant extract, an alcohol, and the like. Examples of the medicinal ingredient include other moisturizing ingredients such as sodium hyaluronate.
  • The content of the plant of the present invention in the quasi drug or cosmetics is preferably 0.01 to 100% by mass, more preferably, 0.05 to 70% by mass, as a dry solid ingredient. Meanwhile, the content of the extract thereof is generally preferably 0.00001 to 100% by mass, more preferably, 0.0001 to 70% by mass, in terms of solid content.
  • The above-mentioned “quasi drug” is a cosmetic showing special effects defined in Article 2(2) of the Pharmaceutical Affairs Law of Japan, the effect is milder than that of pharmaceuticals.
  • EXAMPLES Preparation Example 1 Preparation of Angelicae Dahuricae Radix Extract
  • To 100 g of Angelicae Dahuricae Radix, 5 times amount of petroleum ether was added, and the mixture was stirred for 1 hour at 50° C., followed by extraction and filtration, to prepare a petroleum ether extract. Then the petroleum ether extract was evaporated and dried, to yield approximately 0.9 g of petroleum ether extract of Angelicae Dahuricae Radix.
  • Preparation Example 2 Preparation of Rehmanniae Radix Extract
  • Following the same procedure as Preparation Example 1, except that 100 g of Rehmanniae Radix was used in place of 100 g of Angelicae Dahuricae Radix, a petroleum ether extract was prepared. To the residue prepared by the extraction with the petroleum ether, 5 times amount of 95% ethanol was added, and the mixture was refluxed with stirring at 78° C. for 1 hour, followed by extraction and filtration, to prepare an ethanol extract. Then the ethanol extract was evaporated and dried, to yield approximately 5.0 g of ethanol extract of Rehmanniae Radix.
  • Preparation Example 3 Preparation of Atractylodis Rhizoma Extract
  • Following the same procedure as Preparation Example 1, except that 100 g of Atractylodis Rhizoma was used in place of 100 g of Angelicae Dahuricae Radix, a petroleum ether extract was prepared. The petroleum ether extract was evaporated and dried, to yield approximately 0.8 g of petroleum ether extract of Atractylodis Rhizoma.
  • Preparation Example 4 Preparation of Glycyrrhizae Radix Extract
  • Following the same procedure as Preparation Example 1, except that 100 g of Glycyrrhizae Radix was used in place of 100 g of Angelicae Dahuricae Radix, a petroleum ether extract was prepared. To the residue prepared by the extraction with the petroleum ether, 5 times amount of 95% ethanol was added, and the mixture was refluxed at 78° C., and stirred for 1 hour, followed by extraction and filtration, to prepare an ethanol extract. Then the ethanol extract was evaporated and dried, to yield approximately 9.1 g of ethanol extract of Glycyrrhizae Radix.
  • Preparation Example 5 Preparation of Rhei Rhizoma Extract
  • Following the same procedure as Preparation Example 1, except that 100 g of Rhei Rhizoma was used in place of 100 g of Angelicae Dahuricae Radix, a petroleum ether extract was prepared. To the residue prepared by the extraction with the petroleum ether, 5 times amount of 95% ethanol was added, and the mixture was refluxed with stirring at 78° C. for 1 hour, followed by extraction and filtration, to prepare an ethanol extract. To the resulting residue prepared by the extraction with ethanol, 5 times amount of water was added and the mixture was stirred at 60° C. for 1 hour under ultrasonication, followed by extraction and filtration, to thereby prepare a water extract. Then this water extract was evaporated and dried, to yield approximately 6.9 g of water extract of Rhei Rhizoma.
  • Preparation Example 6 Preparation of Bletilla Tuber Extract
  • Following the same procedure as Preparation Example 1, except that 100 g of Bletilla Tuber was used in place of 100 g of Angelicae Dahuricae Radix, a petroleum ether extract was prepared. The petroleum ether extract was evaporated and dried, to yield 0.4 g of petroleum ether extract of Bletilla Tuber.
  • Preparation Example 7 Preparation of Polygoni Multiflori Radix Extract
  • Following the same procedure as Preparation Example 1, except that 100 g of Polygoni Multiflori Radix was used in place of 100 g of Angelicae Dahuricae Radix, a petroleum ether extract was prepared. The petroleum ether extract was evaporated and dried, to yield approximately 0.2 g of petroleum ether extract of Polygoni Multiflori Radix.
  • Preparation Example 8 Preparation of Platycodi Radix Extract
  • Following the same procedure as Preparation Example 1, except that 100 g of Platycodi Radix was used in place of 100 g of Angelicae Dahuricae Radix, a petroleum ether extract was prepared. The petroleum ether extract was evaporated and dried, to yield approximately 0.5 g of petroleum ether extract of Platycodi Radix.
  • Preparation Example 9 Preparation of Leonuri Herba Extract
  • Following the same procedure as Preparation Example 1, except that 100 g of Leonuri Herba was used in place of 100 g of Angelicae Dahuricae Radix, a petroleum ether extract was prepared. The petroleum ether extract was evaporated and dried, to yield approximately 0.5 g of petroleum ether extract of Leonuri Herba.
  • Preparation Example 10 Preparation of Dioscoreae Rhizoma Extract
  • Following the same procedure as Preparation Example 1, except that 100 g of Dioscoreae Rhizoma was used in place of 100 g of Angelicae Dahuricae Radix, a petroleum ether extract was prepared. The petroleum ether extract was evaporated and dried, to yield approximately 0.3 g of the petroleum ether extract of Dioscoreae Rhizoma.
  • Example 1 Ceramide Production Acceleration Test <Test Solutions and Control Solutions>
  • Preparation Control
    Example Test solution solution
    1, 3, 6, 7, 8, 9, Using ethanol as a Ethanol
    and 10 solvent, 1% w/v content of
    (Petroleum ether each ethanol solution of
    extract) the petroleum ether
    extract was prepared.
    2 and 4 Using ethanol as a Ethanol
    (Ethanol extract) solvent, 1% w/v content of
    each ethanol solution of
    the ethanol extract was
    prepared.
    5 Using 10% ethanol as a 10%
    (Water extract) solvent, 1% w/v content of ethanol
    an ethanol solution of the
    water extract was
    prepared.
  • <Culture Condition>
  • Normal human epidermal keratinocyte (NHEK (F)) was seeded into 6 well plate EpiLife-KG2 (product of KURABO Industries Ltd.), and was cultured until confluent. Then, the culture medium were changed to EpiLife-KG2 (without additive growth factor), and each of the above test solutions and each control solution were added thereto. After culturing for 3 days, cells were collected from the wells one by one.
  • <Lipid Extraction>
  • Lipid was extracted from the collected cells following Bligh and Dyer method. After the extraction, lipid extract was dried to solid with nitrogen, the solid was dissolved again in a mixed liquid of chloroform and methanol, to prepare a lipid sample. The amount of protein was quantified by BCA method.
  • <Analysis of Ceramide Level>
  • The extracted lipid was analyzed with a thin-layer chromatography (TLC). The lipid was horizontally developed twice with a solvent (chloroform:methanol:acetic acid=190:9:1), blow-dried, sprayed with a coloring solution of copper sulfate, and heated on a hot plate, whereby the ceramide was detected. Thereafter, the obtained values were divided by each protein amount to calculate each ceramide amount (Table 1). The values in the Table are relative values to the ceramide amount of control (a sample added the above-mentioned control solution) set as 1.
  • TABLE 1
    Ceramide amount
    Plant extract (Relative value)
    Angelicae Dahuricae Radix 4.3
    (petroleum ether extract)
    Rehmanniae Radix 3.3
    (Ethanol extract)
    Atractylodis Rhizoma 2.0
    (Petroleum ether extract)
    Glycyrrhizae Radix 7.9
    (Ethanol extract)
    Rhei Rhizoma 4.7
    (Water extract)
    Bletilla Tuber 2.0
    (Petroleum ether extract)
    Polygoni Multiflori Radix 5.1
    (Petroleum ether extract)
    Platycodi Radix 2.4
    (Petroleum ether extract)
    Leonuri Herba 4.9
    (Petroleum ether extract)
    Dioscoreae Rhizoma 7.1
    (Petroleum ether extract)
  • As shown in Table 1, ceramide production-accelerating effect on human keratinocytes by the plant extract of the present invention was confirmed.

Claims (8)

1. A ceramide production-accelerating agent comprising a plant selected from the group consisting of Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma, or an extract thereof as an active ingredient.
2. The ceramide production-accelerating agent according to claim 1, wherein the extract of Angelicae Dahuricae Radix, Atractylodis Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, or Dioscoreae Rhizoma is a petroleum ether extract prepared by using a petroleum ether as an extraction solvent.
3. The ceramide production-accelerating agent according to claim 1, wherein the extract of Rehmanniae Radix or Glycyrrhizae Radix is an ethanol extract prepared by successively using a petroleum ether and ethanol as extraction solvents.
4. The ceramide production-accelerating agent according to claim 1, wherein the extract of Rhei Rhizoma is a water extract prepared by successively using a petroleum ether, ethanol, and water as extraction solvents.
5. Use of a plant selected from the group consisting of Angelicae Dahuricae Radix, Rehmanniae Radix, Atractylodis Rhizoma, Glycyrrhizae Radix, Rhei Rhizoma, Bletilla Tuber, Polygoni Multiflori Radix, Platycodi Radix, Leonuri Herba, and Dioscoreae Rhizoma, or an extract thereof for the manufacture of the ceramide production-accelerating agent according to any one of claims 1 to 4.
6. A moisturizing agent comprising a plant selected from the group consisting of Leonuri Herba and Dioscoreae Rhizoma, or an extract thereof as an active ingredient.
7. The moisturizing agent according to claim 6, wherein the extract of Leonuri Herba or Dioscoreae Rhizoma is a petroleum ether extract prepared by using a petroleum ether as an extraction solvent.
8. Use of a plant selected from the group consisting of Leonuri Herba and Dioscoreae Rhizoma, or an extract thereof for the manufacture of the moisturizing agent according to claim 6 or 7.
US13/059,329 2008-08-18 2009-08-17 Promotors of Ceramide's Generation Abandoned US20110200694A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN200810145900.X 2008-08-18
CN200810145900 2008-08-18
CN200810145899.0 2008-08-18
CN200810145899 2008-08-18
CN200910118746 2009-03-04
CN2009101187461A CN101653561B (en) 2008-08-18 2009-03-04 Ceramide production accelerant
CN 200910118747 CN101653537B (en) 2008-08-18 2009-03-04 Ceramide production accelerant
CN200910118747.6 2009-03-04
PCT/CN2009/073291 WO2010020165A1 (en) 2008-08-18 2009-08-17 Promotors of ceramide’s generation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/073291 A-371-Of-International WO2010020165A1 (en) 2008-08-18 2009-08-17 Promotors of ceramide’s generation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/600,701 Division US10610561B2 (en) 2008-08-18 2015-01-20 Ceramide production-accelerating agent

Publications (1)

Publication Number Publication Date
US20110200694A1 true US20110200694A1 (en) 2011-08-18

Family

ID=43971183

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/059,329 Abandoned US20110200694A1 (en) 2008-08-18 2009-08-17 Promotors of Ceramide's Generation
US14/600,701 Active 2033-03-23 US10610561B2 (en) 2008-08-18 2015-01-20 Ceramide production-accelerating agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/600,701 Active 2033-03-23 US10610561B2 (en) 2008-08-18 2015-01-20 Ceramide production-accelerating agent

Country Status (4)

Country Link
US (2) US20110200694A1 (en)
EP (1) EP2332558B1 (en)
JP (2) JP2012500231A (en)
WO (1) WO2010020165A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610561B2 (en) 2008-08-18 2020-04-07 Zhongshan Hospital of Fudan University Ceramide production-accelerating agent

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011231057A (en) * 2010-04-28 2011-11-17 Kao Corp Ceramide production enhancer
JP5649995B2 (en) * 2011-01-31 2015-01-07 日本メナード化粧品株式会社 Ceramide production promoter
JP2013193959A (en) * 2012-03-15 2013-09-30 Maruzen Pharmaceut Co Ltd Hair springiness and stiffness improving agent
JP6242575B2 (en) * 2013-01-09 2017-12-06 御木本製薬株式会社 Dendritic elongation inhibitor
JP6646408B2 (en) * 2015-11-10 2020-02-14 日本メナード化粧品株式会社 Ceramide production promoter

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60258104A (en) * 1984-06-06 1985-12-20 Inahata Koryo Kk Cosmetic composition having moisture retention
JPH0597653A (en) * 1991-09-18 1993-04-20 Tsuneo Nanba Cosmetic
JP3205581B2 (en) * 1991-12-07 2001-09-04 有限会社野々川商事 Collagen crosslinking inhibitor
JPH09176030A (en) * 1995-12-27 1997-07-08 Lion Corp Medicine for stimulating secretion of sebum
JPH10139639A (en) * 1996-11-07 1998-05-26 Kao Corp Hair growth-inhibiting agent
JPH10152421A (en) 1996-11-22 1998-06-09 Kao Corp Improvement of tension, elasticity and feeling of hair
JPH11180856A (en) * 1997-12-20 1999-07-06 Nonogawa Shoji Kk Composition for bathing agent
CN1203097A (en) * 1998-06-26 1998-12-30 林旭 Compound ointment for treating rheumatic disease and preparing process thereof
JP4601088B2 (en) * 1998-08-07 2010-12-22 ピアス株式会社 Ceramide synthesis promoter that enhances sphingomyelinase activity
CN1098676C (en) * 1998-09-18 2003-01-15 张天福 Natural plant skin protection beautifying liquid
JP3816262B2 (en) 1998-09-30 2006-08-30 花王株式会社 Ceramide production promoter
JP3051119B1 (en) * 1999-03-25 2000-06-12 日華化学株式会社 Disinfectant composition
JP2000281528A (en) * 1999-03-31 2000-10-10 Ichimaru Pharcos Co Ltd Cosmetic composition
JP2001158735A (en) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd Agent for preventing and improving periodontal disease
JP2001158736A (en) 1999-11-30 2001-06-12 Snow Brand Milk Prod Co Ltd Agent for preventing and improving osteoarthropathy
FR2811561B1 (en) * 2000-07-13 2003-03-21 Oreal COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND / OR A CHEMICAL OR BIOLOGICAL PRECURSOR OR DERIVATIVE THEREOF, AND A METALLOPROTEINASE INHIBITOR
JP4796734B2 (en) * 2002-03-19 2011-10-19 株式会社ディーエイチシー Matrix metalloprotease activity inhibitor
CN1395937A (en) 2002-08-15 2003-02-12 刘莉 Application of chrysopdyose in preparing medicine to treat inflammatory enteropathy and its preparing process
CN1205919C (en) * 2003-03-19 2005-06-15 湖南师范大学 Freckle-diminishing moisture-retaining skin-care cream
CN1533701A (en) 2003-03-28 2004-10-06 戚海波 Eaible beautifying and skin protection milk powder liquid state milk specially prepared concentrated milk
JP2006124350A (en) * 2004-11-01 2006-05-18 Nippon Menaade Keshohin Kk Nmf production promoter
JP2006342066A (en) * 2005-06-07 2006-12-21 Ogawa & Co Ltd Moisturizing plant extract, and external preparation, cosmetic, bathing agent and detergent each containing the extract
JP2006347907A (en) * 2005-06-14 2006-12-28 Ogawa & Co Ltd Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract
JP2006347902A (en) * 2005-06-14 2006-12-28 Ogawa & Co Ltd Moisture retention plant extract, and external preparation, cosmetic product, bathing agent and detergent containing the extract
CN1947696A (en) * 2005-10-14 2007-04-18 范红 Formula of traditional Chinese medicine with white-skinned face function
CN1977809A (en) * 2005-12-01 2007-06-13 上海莲氏轩生物工程有限公司 Plant anti-wrinkle function lotion
CN1977812A (en) * 2005-12-02 2007-06-13 上海莲氏轩生物工程有限公司 Plant moisturizing function lotion
CN101011333A (en) * 2006-01-31 2007-08-08 通化万盛保健食品有限责任公司 Humidity preserving beauty article and process for its preparation
CN101062002B (en) * 2006-04-24 2010-06-16 王筑平 Skin-care combination including plant extracts
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
JP2008255051A (en) * 2007-04-04 2008-10-23 Maruzen Pharmaceut Co Ltd Ceramide synthesis promoter, skin barrier function-ameliorating agent, and agent for preventing and treating disease caused by ceramide synthesis trouble
JP2012500231A (en) 2008-08-18 2012-01-05 復旦大学附属中山医院 Ceramide production promoter

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Luo et al., Toxicity of Petroleum Ether Extract from Herba Leonuri after Oral administration in Rats, Clinical Pharm, April 2008, 43: 499-501 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610561B2 (en) 2008-08-18 2020-04-07 Zhongshan Hospital of Fudan University Ceramide production-accelerating agent

Also Published As

Publication number Publication date
EP2332558B1 (en) 2018-10-17
EP2332558A1 (en) 2011-06-15
JP5940568B2 (en) 2016-06-29
JP2012500231A (en) 2012-01-05
US20150132415A1 (en) 2015-05-14
US10610561B2 (en) 2020-04-07
JP2014074074A (en) 2014-04-24
EP2332558A4 (en) 2013-05-15
WO2010020165A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
US10610561B2 (en) Ceramide production-accelerating agent
CN106214592B (en) Hair follicle nutrient liquor composition and preparation method thereof
CN101653561B (en) Ceramide production accelerant
JP2011079755A (en) Ceramide production promoter
KR101922635B1 (en) Cosmetic composition for improving skin inflammation comprising horse oil and sprout extracts
CN103932962A (en) Chinese herbal medicine acne-removal repair compound cosmetic and preparation method thereof
KR20170137544A (en) Composition for improving skin condition comprising herb extracts mixture
JP5616045B2 (en) Ceramide production promoter and moisturizer
JPH1095735A (en) Hyaluronic acid productivity potentiator
KR20170137552A (en) Composition for improving skin condition comprising herb extracts mixture
KR20170136378A (en) Composition for improving skin condition comprising herb extracts mixture
CN106309911B (en) Anti-aging traditional Chinese medicine composition and preparation method thereof
KR102598348B1 (en) Composition for controlling sebum and reducing the skin pore
KR101914969B1 (en) Hair cosmetic composition containing extract of fermented oriental medicinal herbs
KR20170136911A (en) Composition for improving skin condition comprising herb extracts mixture
KR20170136930A (en) Composition for improving skin condition comprising herb extracts mixture
KR20160003914A (en) Cosmetic composition for anti-inflammation or improving skin trouble containing herb extracts
KR20170136913A (en) Composition for improving skin condition comprising herb extracts mixture
KR20170137548A (en) Composition for improving skin condition comprising herb extracts mixture
JP6723979B2 (en) Wrinkle improver
CN111773149A (en) Skin care composition and preparation method thereof
CN115996739B (en) Compositions comprising extracts of Carum Carvi and Rosmarinus officinalis and methods of use thereof
CN115768453B (en) Compositions comprising extracts of Carum Carvi and Rosmarinus officinalis and methods of use thereof
KR101857543B1 (en) Cosmetic composition containing extract of mixed herbs for promoting of collagen synthesis
KR100728444B1 (en) Cosmetics comprising a extract of natural herb

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY, CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:QIN, WAN ZHANG;YANG, CHUN XIN;KONG, FAN QI;AND OTHERS;SIGNING DATES FROM 20101122 TO 20101223;REEL/FRAME:025856/0751

Owner name: KAO CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:QIN, WAN ZHANG;YANG, CHUN XIN;KONG, FAN QI;AND OTHERS;SIGNING DATES FROM 20101122 TO 20101223;REEL/FRAME:025856/0751

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION